BR112022021204A2 - Polipeptídeos, proteínas heterodiméricas, ácido nucleico, células hospedeiras, método, composição farmacêutica e método de tratamento de uma espécie de animal de companhia, métodos para reduzir a atividade de sinalização de il13 e/ou il4 e para detectar il13 ou il4 em uma amostra - Google Patents

Polipeptídeos, proteínas heterodiméricas, ácido nucleico, células hospedeiras, método, composição farmacêutica e método de tratamento de uma espécie de animal de companhia, métodos para reduzir a atividade de sinalização de il13 e/ou il4 e para detectar il13 ou il4 em uma amostra

Info

Publication number
BR112022021204A2
BR112022021204A2 BR112022021204A BR112022021204A BR112022021204A2 BR 112022021204 A2 BR112022021204 A2 BR 112022021204A2 BR 112022021204 A BR112022021204 A BR 112022021204A BR 112022021204 A BR112022021204 A BR 112022021204A BR 112022021204 A2 BR112022021204 A2 BR 112022021204A2
Authority
BR
Brazil
Prior art keywords
polypeptides
heterodimeric proteins
methods
species
companion animal
Prior art date
Application number
BR112022021204A
Other languages
English (en)
Inventor
Jiann Li Shyr
Nguyen Lam
Chu Qingyi
Qian Fawn
Chin Richard
Zhan Hangjun
Original Assignee
Kindred Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindred Biosciences Inc filed Critical Kindred Biosciences Inc
Publication of BR112022021204A2 publication Critical patent/BR112022021204A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/544—IL-14

Abstract

POLIPEPTÍDEOS, PROTEÍNAS HETERODIMÉRICAS, ÁCIDO NUCLEICO, CÉLULAS HOSPEDEIRAS, MÉTODO, COMPOSIÇÃO FARMACÊUTICA E MÉTODO DE TRATAMENTO DE UMA ESPÉCIE DE ANIMAL DE COMPANHIA, MÉTODOS PARA REDUZIR A ATIVIDADE DE SINALIZAÇÃO DE IL13 E/OU IL4 E PARA DETECTAR IL13 OU IL4 EM UMA AMOSTRA. São fornecidas várias realizações relacionadas a polipeptídeos contíguos IL13R/IL4R e proteínas heterodiméricas IL13R/IL4R de espécies animais de companhia e que se ligam à IL13 e/ou IL4, incluindo polipeptídeos contíguos e proteínas heterodiméricas de ação prolongada. Tais proteínas heterodiméricas podem ser usadas em métodos para tratar condições induzidas por IL13 e/ou IL4 em animais de companhia, como caninos, felinos e equinos.
BR112022021204A 2020-04-22 2021-04-22 Polipeptídeos, proteínas heterodiméricas, ácido nucleico, células hospedeiras, método, composição farmacêutica e método de tratamento de uma espécie de animal de companhia, métodos para reduzir a atividade de sinalização de il13 e/ou il4 e para detectar il13 ou il4 em uma amostra BR112022021204A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014090P 2020-04-22 2020-04-22
US202063014573P 2020-04-23 2020-04-23
PCT/US2021/028679 WO2021216899A1 (en) 2020-04-22 2021-04-22 Il4/il13 receptor molecules for veterinary use

Publications (1)

Publication Number Publication Date
BR112022021204A2 true BR112022021204A2 (pt) 2022-12-06

Family

ID=78270112

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021204A BR112022021204A2 (pt) 2020-04-22 2021-04-22 Polipeptídeos, proteínas heterodiméricas, ácido nucleico, células hospedeiras, método, composição farmacêutica e método de tratamento de uma espécie de animal de companhia, métodos para reduzir a atividade de sinalização de il13 e/ou il4 e para detectar il13 ou il4 em uma amostra

Country Status (9)

Country Link
EP (1) EP4139344A1 (pt)
JP (1) JP2023522676A (pt)
KR (1) KR20230005880A (pt)
CN (1) CN116034112A (pt)
AU (1) AU2021259785A1 (pt)
BR (1) BR112022021204A2 (pt)
CA (1) CA3173927A1 (pt)
MX (1) MX2022013149A (pt)
WO (1) WO2021216899A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
WO2018195388A1 (en) 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023289A1 (en) * 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
WO2018195388A1 (en) * 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use

Also Published As

Publication number Publication date
MX2022013149A (es) 2023-02-09
AU2021259785A1 (en) 2022-11-17
EP4139344A1 (en) 2023-03-01
CN116034112A (zh) 2023-04-28
CA3173927A1 (en) 2021-10-28
WO2021216899A1 (en) 2021-10-28
JP2023522676A (ja) 2023-05-31
KR20230005880A (ko) 2023-01-10

Similar Documents

Publication Publication Date Title
BR112022021204A2 (pt) Polipeptídeos, proteínas heterodiméricas, ácido nucleico, células hospedeiras, método, composição farmacêutica e método de tratamento de uma espécie de animal de companhia, métodos para reduzir a atividade de sinalização de il13 e/ou il4 e para detectar il13 ou il4 em uma amostra
Duncan et al. The life cycle of Strongylus vulgaris in the horse
BRPI0606363A2 (pt) método para o isolamento e/ou a purificação de ácidos nucleicos ácido nucleico, e, método para a imobilização de ácidos nucleicos em uma matriz
Al Abri et al. Genome-wide scans reveal a quantitative trait locus for withers height in horses near the ANKRD1 gene
RU2015111205A (ru) Генетические маркеры устойчивости к маститу
Mishra et al. Single nucleotide polymorphisms in 5’upstream region of bovine TLR4 gene affecting expression profile and transcription factor binding sites
Jabbar et al. The mitochondrial genome of Aelurostrongylus abstrusus—diagnostic, epidemiological and systematic implications
BR112022021216A2 (pt) Anticorpos, ácido nucleico, célula hospedeira, composições farmacêuticas, métodos de produção de um anticorpo e de tratamento de uma espécie de animal de companhia e métodos para reduzir a função de sinalização de il31 em uma célula e para detectar il31 em uma amostra
Li et al. Molecular characterization of RIG-I, STAT-1 and IFN-beta in the horseshoe bat
Pratiwi et al. Novel SNP of calpain-1 (CAPN1) gene and its association with carcass and meat characteristics traits in Bali cattle.
Şahin et al. Identification of bovine leukocyte adhesion deficiency (BLAD) and bovine citrullinaemia (BC) alleles in Holstein cows reared in Antalya region
CN106086232B (zh) 一种用于鉴别羊口疮病毒和羊痘病毒的二重pcr检测引物、试剂盒和检测方法
Paek et al. Application of PCR-RFLP for quick identification of MSTN mutants in MSTN mutant pig breeding
Patra et al. Single nucleotide polymorphism and expression studies of the interferon gamma gene and its role against Haemonchus contortus in Garole and Sahabadi sheep
Ghassani et al. Association of Quantitative Characteristics with Growth Hormone Gene (GH Gene) in Kerinci Duck Using PCR-RFLP Method
Goshu et al. Novel copy number variations of the CHRM3 gene associated with gene expression and growth traits in Chinese Datong yak (Bos grunniens)
Illig et al. TRPC4 ion channel protein is selectively expressed in a subpopulation of dopamine neurons in the ventral tegmental area
El-Mahdy Othman Mitochondrial DNA as a marker for genetic diversity and evolution
CA3101674A1 (en) In vitro method for monitoring the pathogen load in an animal population
Safari et al. Identification of Single Nucleotide Polymorphism in Exon 3 of TLR4 Gene and its Association with Somatic Cell Count in Dairy Cattle
RU2011118970A (ru) Диагностический тест для выявления митохондриальной днк животных в кормах и мясных продуктах
Eko et al. Identification and Prevalence of Brucella Species Circulating among Cattle Slaughtered in the Douala and Buea Municipalities of Cameroon
JP2013009678A (ja) プライマー配列
Arbizu et al. The complete mitochondrial genome of a Peruvian creole cattle (Bos taurus) and its phylogenetic analysis
Ahmad et al. Recent Trends In Livestock Innovative Technologies